Search

© 2022 Verduci Editore s.r.l. All rights reserved.Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies.

Purpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia. © 2021 Zerbinis Publications. All rights reserved.

The aim of this study was to evaluate the effect of autogenous tooth bone graft (ATBG) combined with platelet-rich fibrin (PRF) on bone healing in rabbit peri-implant osseous defects. Eighteen New Zealand rabbits were divided into 3 groups. Bone defects were prepared in each rabbit, and then an implant cavity was created in the defects. Dental implants were placed, and the peri-implant bone defects were treated with the following 3 methods: no graft material was applied in the control group, bone defects were treated with ATBG in the ATBG group, and bone defects were treated with ATBG combined with PRF in the ATBG+PRF group. After 28 days, the rabbits were sacrificed, and the dental implants with surrounding bone were removed. New bone formation and the percentage of bone-to-implant contact (BIC) were determined with histomorphometric evaluations. New bone formation was significantly higher in the ATBG+PRF group than the control and ATBG groups (P< .05). In addition, BIC was significantly higher in the ATBG+PRF group than in the control and ATBG groups (P< .05). The combination of ATBG with PRF contributed to bone healing in rabbits with peri-implant bone defects. C1 [Kizildag, Alper] Pamukkale Univ, Fac Dent, Dept Periodontol, Denizli, Turkey. [Tasdemir, Ufuk] Pamukkale Univ, Fac Dent, Dept Maxillofacial Surg, Denizli, Turkey. [Arabaci, Taner] Ataturk Univ, Fac Dent, Dept Periodontol, Erzurum, Turkey. [Kizildag, Canan Aksu] Pamukkale Univ, Fac Dent, Dept Orthodont, Denizli, Turkey. [Albayrak, Mevlut] Ataturk Univ, Hlth Serv Vocat Training Sch, Med Lab Dept, Erzurum, Turkey. [Sahin, Barbaros] Pamukkale Univ, Expt Surg Applicat & Res Ctr, Denizli, Turkey.

Caffeic acid phenethyl ester (CAPE) is used as a therapeutic agent to prevent bone loss. We determined the effects of systemically administered CAPE on alveolar bone loss and oxidative stress in diabetic rats with experimental periodontitis. Forty male rats were divided into four equal groups: control, experimental periodontitis (EP), EP-diabetes mellitus (EP-DM) and EP-DM-CAPE. DM was induced by streptozotocin, then lipopolysaccharide was injected to induce periodontitis. CAPE was administered to the EP-DM-CAPE group daily for 15 days. Then, serum samples were taken and the rats were sacrificed for histological analyses. Serum interleukin (IL-1 beta) and oxidative stress also were evaluated. Alveolar bone loss was assessed histomorphometrically. Alveolar bone loss and IL-1 beta levels were significantly less in the EP-DM-CAPE and EP groups compared to the EP-DM group. Oxidative stress was significantly less in the EP-DM-CAPE group compared to the EP and EP-DM groups. Receptor activator of nuclear factor kappa-B ligand (RANKL) levels were significantly higher in the EP-DM group compared to the disease groups. CAPE significantly reduced RANKL levels in the EP-DM-CAPE group compared to the EP-DM group. We found that CAPE treatment significantly inhibited DM induced oxidative stress and RANKL induced osteoclastogenesis and alveolar bone loss in diabetic rats with periodontitis. C1 [Kizildag, Alper; Balseven, Havva Muge] Pamukkale Univ, Fac Dent, Dept Periodontol, TR-20070 Denizli, Turkey. [Arabaci, Taner] Ataturk Univ, Fac Dent, Dept Periodontol, Erzurum, Turkey. [Albayrak, Mevlut] Ataturk Univ, Hlth Serv Vocat Training Sch, Med Lab Dept, Erzurum, Turkey. [Kizildag, Canan Aksu] Pamukkale Univ, Fac Dent, Dept Orthodont, Denizli, Turkey. [Tasdemir, Ufuk] Pamukkale Univ, Fac Dent, Dept Maxillofacial Surg, Denizli, Turkey.

Background Osteoarthritis (OA) is a degenerative chronic illness that most frequently occurs in the knee joint. Daidzein (DZ) an isoflavone has anti-inflammatory and antioxidant activity. The aim of this study was to evaluate the effectiveness of DZ as a treatment for experimental knee OA (KOA) in rats. Method An experimental KOA model was induced by monosodium iodoacetate (MIA) in rats. Thereafter, 49 Wistar albino male rats (250-300 g, 12-16 weeks old) were randomly divided into 7 groups: C (healthy control); DC (KOA + saline); hyaluronic acid (HA); HA+ intraarticular (ia) DZ; oral (po) DZ; ia DZ; HA + po DZ groups. DZ and/or HA were administered intraarticularly to the rats as 50 mu L on days 1, 7, 14, and 21. Alternatively, the DZ was administered orally as 0.5 mL twice daily for 21 days. After the treatment, rats were sacrificed by decapitation under general anesthesia. Serum samples were analyzed to determine the total oxidant status (TOS) and total antioxidant status (TAS) and the levels of TNF-alpha, IL-1 beta, MMP-13, and DZ. Knee joint samples underwent histopathological examination, and TNF-alpha, IL-1 beta, NOS2, and MMP-13 were analyzed with immunohistochemical methods. Results HA, DZ, and DZ + HA effectively reduced the levels of TNF-alpha, IL-1 beta, and MMP-13 in the serum of the DC group (p < 0.001). In groups that received HA, DZ, or DZ + HA, the serum TAS increased compared with the DC group (p < 0.05). When the DZ + HA combination was used, a more pronounced reduction in the levels of TNF alpha, NOS2, IL-1 beta, and MMP-13 was observed in knee joints. In addition, the cracks on the cartilage surface and fibrillation were completely improved in the groups that received HA, DZ, or DZ + HA compared with the DC group. Conclusion DZ had anti-inflammatory and antioxidant effects in a rat OA model. Therefore, DZ, as monotherapy or especially in combination with HA, may be a promising and beneficial therapy for OA. C1 [Gundogdu, Gulsah] Pamukkale Univ, Fac Med, Dept Physiol, Denizli, Turkey. [Miloglu, Fatma Demirkaya] Ataturk Univ, Fac Pharm, Dept Analyt Chem, Erzurum, Turkey. [Gundogdu, Koksal] Denizli State Hosp, Dept Orthoped & Traumatol, Denizli, Turkey. [Tasci, Seymanur Yilmaz] Ataturk Univ, Fac Med, Dept Physiol, Erzurum, Turkey. [Albayrak, Mevlut] Ataturk Univ, Hlth Serv Vocat Coll, Dept Med Lab Tech, Erzurum, Turkey. [Demirci, Tuba] Ataturk Univ, Fac Med, Dept Histol & Embryol, Erzurum, Turkey. [Cetin, Meltem] Ataturk Univ, Fac Pharm, Dept Pharmaceut Technol, Erzurum, Turkey.

Background/purpose: Caffeic acid phenethyl ester (CAPE) is an antioxidant which is decreases the bone resorption and enhances the bone healing. The aim of this study was to investigate the effects of administering systemic CAPE on alveolar bone loss in rats with experimental periodontitis. Materials and methods: Thirty male Sprague Dawley rats were divided into three groups: control, endotoxin-induced periodontitis (EP), and EP treated with CAPE (EP-CAPE). Endotoxin was injected into the gingiva of test rats on days 1, 3, and 5, whereas saline was injected into the control rats. The EP-CAPE group received 10 mmol/kg/day CAPE intraperitoneally for 28 consecutive days. Saline was given in the control and EP groups in the same manner. At the end of the study, intracardiac blood samples were obtained, and the rats were sacrificed. Alveolar bone loss was analyzed with histometric measurements. The oxidative stress index (OSI) was used to evaluate the oxidative stress. The receptor activator of the nuclear factor kappa B ligand (RANKL) level was analyzed stereologically. Results: CAPE administration significantly decreased the serum OSI and interleukin-1 beta levels. Alveolar bone loss was statistically higher in the EP group compared with the EP-CAPE group (P < 0.05). Immunohistochemical analyses of the RANKL were significantly lower in the EP-CAPE group than in the EP group (P < 0.05). Conclusion: This experimental study revealed that CAPE administration significantly prevented alveolar bone loss and stimulated periodontal tissue healing. (C) 2019 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. C1 [Kizildag, Alper] Pamukkale Univ, Fac Dent, Dept Periodontol, TR-20070 Denizli, Turkey. [Arabaci, Taner] Ataturk Univ, Fac Dent, Dept Periodontol, Erzurum, Turkey. [Albayrak, Mevlut] Ataturk Univ, Hlth Serv Vocat Training Sch, Med Lab Dept, Erzurum, Turkey. [Tasdemir, Ufuk; Senel, Erman] Pamukkale Univ, Fac Dent, Dept Maxillofacial Surg, Denizli, Turkey. [Dalyanoglu, Mukaddes] Pamukkale Univ, Med Sch, Dept Physiol, Denizli, Turkey. [Demirci, Elif] Ataturk Univ, Med Sch, Med Biol Dept, Erzurum, Turkey.

Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological and hematological disorders, and today, most TPE procedures are done for the same reasons. The only historical change has been an increase in TPE procedures in renal conditions. Currently, renal conditions were more frequently an indication for TPE than rheumatic conditions. Fresh frozen plasma was the most frequently used replacement fluid, followed by 5% albumin, used in 57.9% and 34.6% of procedures, respectively. The most frequently used anticoagulants in TPE were ACD-A and heparin/ACD-A, used with 1671 (52.2%) and 1164 (36.4%) patients, respectively. The frequency of adverse events (AEs) was 12.6%. The most common AEs were hypocalcemia-related symptoms, hypotension, and urticaria. We encountered no severe AEs that led to severe morbidity and mortality. Overall, more than two thirds of the patients showed improvement in the underlying disease. Here, we report on a nationwide survey on TPE activity in Turkey. We conclude that there has been a great increase in apheresis science, and the number of TPE procedures conducted in Turkey has increased steadily over time. Finally, we would like to point out that our past experiences and published international guidelines were the most important tools in gaining expertise regarding TPE. © 2019 Elsevier Ltd

Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological and hematological disorders, and today, most TPE procedures are done for the same reasons. The only historical change has been an increase in TPE procedures in renal conditions. Currently, renal conditions were more frequently an indication for TPE than rheumatic conditions. Fresh frozen plasma was the most frequently used replacement fluid, followed by 5% albumin, used in 57.9% and 34.6% of procedures, respectively. The most frequently used anticoagulants in TPE were ACD-A and heparin/ACD-A, used with 1671 (52.2%) and 1164 (36.4%) patients, respectively. The frequency of adverse events (AEs) was 12.6%. The most common AEs were hypocalcemia-related symptoms, hypotension, and urticaria. We encountered no severe AEs that led to severe morbidity and mortality. Overall, more than two thirds of the patients showed improvement in the underlying disease. Here, we report on a nationwide survey on TPE activity in Turkey. We conclude that there has been a great increase in apheresis science, and the number of TPE procedures conducted in Turkey has increased steadily over time. Finally, we would like to point out that our past experiences and published international guidelines were the most important tools in gaining expertise regarding TPE.

Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological and hematological disorders, and today, most TPE procedures are done for the same reasons. The only historical change has been an increase in TPE procedures in renal conditions. Currently, renal conditions were more frequently an indication for TPE than rheumatic conditions. Fresh frozen plasma was the most frequently used replacement fluid, followed by 5% albumin, used in 57.9% and 34.6% of procedures, respectively. The most frequently used anticoagulants in TPE were ACD-A and heparin/ACD-A, used with 1671 (52.2%) and 1164 (36.4%) patients, respectively. The frequency of adverse events (AEs) was 12.6%. The most common AEs were hypocalcemia-related symptoms, hypotension, and urticaria. We encountered no severe AEs that led to severe morbidity and mortality. Overall, more than two thirds of the patients showed improvement in the underlying disease. Here, we report on a nationwide survey on TPE activity in Turkey. We conclude that there has been a great increase in apheresis science, and the number of TPE procedures conducted in Turkey has increased steadily over time. Finally, we would like to point out that our past experiences and published international guidelines were the most important tools in gaining expertise regarding TPE. C1 [Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey. [Medeni, Serife Solmaz] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol, Izmir, Turkey. [Demirkan, Fatih] Dokuz Eylul Univ, Dept Internal Med, Div Hematol, Fac Med,HCT Unit, Izmir, Turkey. [Besisik, Sevgi Kalayoglu; Dadin, Senem Altay] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkey. [Cagliyan, Gulsum Akgun; Hacioglu, Sibel Kabukcu; Sari, Ismail] Pamukkale Univ, Dept Internal Med, Div Hematol, Denizli, Turkey. [Sahin, Deniz Goren] Istanbul Bilim Univ, Sch Med, Dept Hematol, Istanbul, Turkey. [Sahin, Deniz Goren; Arat, Mutlu] Sisli Florence Nightingale Hosp, Stem Cell Transplantat Unit, Istanbul, Turkey. [Dagdas, Simten; Ozet, Gulsum] Ankara Numune Training & Res Hosp, Dept Hematol, Ankara, Turkey. [Kutlu, Nermin; Akyol, Tulay Karaagac] Hacettepe Univ, Sch Med, Therapeut Apheresis Unit, Ankara, Turkey. [Ozcebe, Osman Ilhami] Hacettepe Univ, Sch Med, Dept Hematol, Ankara, Turkey. [Teke, Hava Uskudar] Eskisehir Osmangazi Univ, Sch Med, Dept Internal Med, Div Hematol, Eskisehir, Turkey. [Unal, Demet Kiper; Guner, Naile; Payzin, Bahriye] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Hematol, Izmir, Turkey. [Tombak, Anil] Mersin Univ, Fac Med, Dept Internal Med, Div Heamatol, Mersin, Turkey. [Celik, Halil] Mersin Univ, Fac Med, Dept Internal Med, Mersin, Turkey. [Bay, Ilker; Kiki, Ilhami] Ataturk Univ, Sch Med, Dept Internal Med, Div Hematol, Erzurum, Turkey. [Ozgur, Gokhan] Gulhane Training & Res Hosp, Hematol & HCT Clin, Ankara, Turkey. [Erkurt, Mehmet Ali; Kuku, Irfan] Inonu Univ, Fac Med, Dept Internal Med, Div Hematol, Malatya, Turkey. [Ozatli, Duzgun; Meletli, Ozgur] Ondokuz Mayis Univ, Fac Med, Dept Hematol, Samsun, Turkey. [Demircioglu, Sinan; Demir, Cengiz] Yuzuncu Yil Univ, Fac Med, Dept Internal Med, Div Hematol, Van, Turkey. [Kurtoglu, Erdal] Univ Hlth Sci, Antalya Training & Res Hosp, Dept Hematol, Antalya, Turkey. [Vural, Filiz; Tobu, Mahmut] Ege Univ, Fac Med, Dept Internal Med, Div Hematol, Izmir, Turkey. [Karakus, Abdullah; Ayyildiz, Orhan] Dicle Univ, Fac Med, Dept Internal Med, Div Hematol, Diyarbakir, Turkey. [Dal, Mehmet Sinan; Altuntas, Fevzi] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey. [Dal, Mehmet Sinan; Altuntas, Fevzi] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, BMT Unit, Ankara, Turkey. [Ozturk, Berna Afacan; Albayrak, Murat] Univ Hlth Sci, Diskapi Yildirim Beyazit Training & Res Hosp, Hematol & HCT Clin, Ankara, Turkey. [Ocakci, Serkan] Med Pk Izmir Hosp, Dept Hematol, Izmir, Turkey. [Bolaman, Zahit; Cagirgan, Seckin] Adnan Menderes Univ, Fac Med, Dept Internal Med, Div Hematol, Aydin, Turkey. [Sonmez, Mehmet] Karadeniz Tech Univ, Fac Med, Dept Internal Med, Div Hematol, Trabzon, Turkey. [Karakus, Volkan] Mugla Sitki Kocman Univ, Dept Hematol, Training & Res Hosp, Mugla, Turkey. [Sevindik, Omur Gokmen] Firat Univ, Fac Med, Dept Internal Med, Div Hematol, Elazig, Turkey. [Berber, Ilhami] Malatya Training & Res Hosp, Div Hematol, Malatya, Turkey. [Dogu, Mehmet Hilmi] Istanbul Training & Res Hosp, Hematol Clin, Istanbul, Turkey. [Gulturk, Emine] Kartal Dr Lutfi Kirdar Training & Res Hosp, Dept Internal Med, Div Hematol, Istanbul, Turkey. [Ulas, Turgay] Near East Univ, Dept Internal Med, Div Hematol, Nicosia, Cyprus. [Altuntas, Fevzi] Yildirim Beyazit Univ, Fac Med, Dept Internal Med, Div Hematol, Ankara, Turkey.